
GVHD is used primarily to prevent and treat the immune attack response to the patient's body caused by T lymphocytes in allogeneic grafts. This requires not only the prevention of the disease but also the treatment of the disease.
Immunosuppressants are the main drugs for the prevention of GVHD, but it is necessary to pay attention to the dose, duration, and possible adverse reactions, such as immunocompromise, infection, etc.
3.1 Before taking medication, it is necessary to fully understand the patient's medical history, condition, and medication history to avoid drug interactions or adverse reactions.
3.2 During the medication process, it is necessary to pay close attention to the changes in the patient's condition and adjust the treatment plan in time.
3.3 Pay attention to the preservation and use of drugs to avoid drug factors such as expiration and deterioration affecting the treatment effect.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3662024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:792025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:932025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: